Avara Pharmaceutical Services has signed an agreement with Pfizer to acquire the Liscate, Italy sterile manufacturing facility.
Avara Pharmaceutical Services is a contract manufacturing and technical services organization providing both API formulation and manufacturing, along with secondary formulation, manufacturing and packaging of small molecule drugs, including highly potent compounds. Avara has secondary manufacturing technologies including granulation, coating, blending, encapsulation, compression and drying of tablets and capsules.
Avara Pharmaceutical Services now has six sites. Two in the US, including the corporate HQs; one in Puerto Rico, one in the UK, one in Ireland and this new additional site in Italy.
"As we celebrate another important milestone, we continue with great confidence to build a pharmaceutical services company with complementary offerings in key regions in this rapidly growing market. Each site has significant professional experience, state of the art capability and a long history of delivering high quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements in every major market around the world. The people who are a part of the Avara team are the key to our long-term success," said Timothy C. Tyson, Chairman and CEO. "We are focused on delivering on our commitments and earning the trust of every customer we deal with."